InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,963.17
(
-0.37%
)
US TECH 100
20,403.40
(
-0.42%
)
Dow Jones
43,821.85
(
-0.31%
)
Brent Oil
72.52
(
0.90%
)
Bitcoin
89,404.47
(
-1.28%
)
Post# of 403768
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

loanranger

Send PM Follow Ignore
Followers 209
Posts 32385
Boards Moderated 1
Alias Born 06/30/2009

loanranger

Member Level

Re: MinnieM post# 238586

Tuesday, 08/28/2018 5:12:24 AM

Tuesday, August 28, 2018 5:12:24 AM

Post# of 403768
"Brilacidin couldn't fill that spot since it isn't approved yet."

I guess that's true, but neither is GC4419, RRX-001 or amifostine. So they chose a non-radioprotective drug as a comparitor for 3 radioprotective candidates just because it was an approved treatment for the indication.

Hey...it's their study!
I guess if the indication was the focus Brilacidin may have received a mention since none of the radioprotective candidates has gone beyond Phase 2 either.



But can it core A apple?
Yes Ralph, of course it can core A apple.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent IPIX News
More IPIX News
InvestorsHub NewsWire

Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM

Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM

Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM

Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM

Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM

SANUWAVE Announces Record Quarterly Revenues:  Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM

Start posting your company's news
Only $200 per official company press release!